Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oxford Asymmetry International PLC

Division of Evotec SE

Latest From Oxford Asymmetry International PLC

Evotec Says DiaPep Demise Delays Goals, Spotlight Now On Roche Pact

With the disappearance of DiaPep277 due to presumed fraud, Evotec is now looking to its partnership with Roche in Alzheimer’s to bring the German biotech’s first drug to market - but the timeframe will be longer.

BioPharmaceutical Germany

Terra Infirma: Pharma Dealmaking 2001

With Big Pharma still trying to figure out how to create productive businesses from their mega-mergers, most of the year's high-value M&A saw biotechs buying late-stage or marketed products. But these biotechs are also, with the risk of development failure ever clearer, actively in-licensing and acquiring products and product-creating technologies in order to diversify what are often single-product portfolios. Unlike many Big Pharmas, these companies have been willing to improve existing chemical entities, often exploiting drug delivery and other pharmaceutical sciences. Meanwhile, large companies focused on late-stage in-licensing, in part because they couldn't afford acquisitions--given the valuation disparities between large companies and small ones with valuable late-stage products. Nonetheless, while more affordable than acquisitions, the high price of these deals has transferred the majority of the regulatory and commercial risk to the licensee. As for the early-stage side of the biotech industry: platform companies have not been able to sell their discovery technologies at anything like the prices they expected; as a result, many of them have merged in an effort to create product-focused discovery operations.

BioPharmaceutical Strategy

Chemistry Firms Still Second Fiddle in Biology-Chemistry Mergers

With a scarcity of well-trained chemists and exponentially increasing numbers of genomics-generated targets contributing to an already bulging lead identification/optimization bottleneck, medicinal chemistry capabilities are at a premium. Nonetheless, when it comes to market valuations, biology companies still come out on top. And Celera's recent acquisition of Axys, along with Lexicon Genetics purchase of Coelacanth help prove the point.

BioPharmaceutical Strategy

Isis Innovation LTD

Oxford University's technology transfer group, Isis Innovation, has been around for thirteen years. But it's only since 1997 that the show has really begun.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Evotec SE
  • Senior Management
  • Mario Polywka, CEO
    Malcolm Hay, CFO
    Edwin Moses, Chmn.
    Mike Ratchford, SVP, Bus. Dev., North America
  • Contact Info
  • Oxford Asymmetry International PLC
    Phone: (44) 1235 861561
    151 Milton Park
    Abingdon, OX14 4SD